BOT - Anything but charting, page-3858

First 3858 Last

Share
Profile

Follow
WBA

2,383 Posts.

422

09/03/23

21:20

Post #: 66686965
Share

Originally posted by benno54: ↑

Bot haven't mentioned 7 day letter. if you google fda process and midcycle review etc the fda send a letter 7 days prior. the midcycle review is a 30mins phone call with fda. If bot receive the fda letter requesting certain information they want to discuss in their meeting bot will have to go into a trading halt because they know what the fda needs or is interested in. Get onboard the train now! it's all looking pretty positive.

They also seem to talk about getting off the train at the right station which to me means they might not go all the way and we could be getting a deal done with a big pharma this year. Matt wouldn't be asking for offers if they're going the whole way.

You need to prove to big pharmas that the product can be commercialised and ready to go as that adds value to them. one of the problems brickle had was that they didn't know how to or have a team to commercialise the product. They were hoping for a big pharma to buy them after phase 3 trials, didn't happen so we got to pick it up at excellent value.

And to think most of us have been here waiting for acne and AMR to get approved. I now realise how far away and a couple of cap raises they are. It is really unbelievable how deluded/misinformed about the process I was. this SB deal is going to be turned around in 18 months and has brought everything forward.

Expand

Many of us pointed that out at time @benno54. For Brickle they needed $s there and then. If you now look at US bio in the small firms, many are shredding staff and costs, as well as closing or with JVs / partnerships.
For Vinnie and team timing impeccable, as was hiring Patty, who was the lead through development to end of phase 3. All that IP sat there in her head vital now, as we close in on mid point review and final decision.
We couldn't be doing any more to get it over line.
GLTAH & always DYOR.

BOT Price at posting: 8.2¢ Sentiment: Buy Disclosure: Held
12 Upvote

0 Great analysis

Reply

Top Stories

What's causing the cost-of-living crisis, and how to navigate it

SNX

Sierra Nevada raises $2M for silver exploration at Blackhawk

Week 42 Wrap: HotCopper's top picks; new ASX 200 record; world yawns at war

IRX

InhaleRX snags $38.5M in funding from VC biotech funder Clendon

M4M

Macro, Norden set up transport solutions initiative for West Pilbara

MTH

Mithril's drilling in Mexico picks up silver at 997g/t, gold at 28g/t

TLG

Talga Group wins key permit for flagship graphite mine in Sweden

SWP

Swoop lobs $18M offer at microcap telecom Vonex – in which it holds 19.9%

MKT

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

NVU

Nanoveu surges 10% after benchmark testing for new AI chip begins